Drug intelligence / Profile preview

HN53011

Development stage: Preclinical
Lead developer: Hana Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

HN53011 is an incrementally modified drug (IMD) candidate being developed by Hana Pharm for use in general anesthesia. As an IMD, it is designed to provide clinical improvements over existing anesthetic agents, which may include enhanced safety, efficacy, or pharmacokinetic properties. The program is currently in the discovery phase, and while specific details regarding its chemical structure and molecular target have not been publicly disclosed, it is intended for the induction and maintenance of anesthesia, likely acting on central nervous system targets to facilitate a reversible loss of consciousness.

Beyond the preview

Go deeper on HN53011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN53011.

Explore the full profile